Foxtons Group — Lettings good, Sales held back short term

Foxtons Group (LSE: FOXT)

Last close As at 27/10/2025

GBP0.56

1.30 (2.37%)

Market capitalisation

GBP167m

More on this equity

Research: Real Estate

Foxtons Group — Lettings good, Sales held back short term

Foxtons Group’s Q325 revenue growth was clearly affected by the loss of consumer confidence in the sales market. We, and the company, believe this will probably continue until the end of the year, given the unhelpful headlines relating to potential tax increases in the Autumn Budget and the slower-than-hoped-for decline in interest rates. We have reduced our profit estimates and valuation as a result. However, we believe Foxtons’ strategic direction remains positive, and the internal initiatives previously outlined will bear fruit. Furthermore, the revised medium-term financial targets announced in June are ambitious but achievable, underpinned by structural growth, headquarter-related cost savings, Foxtons’ technology stack and its proprietary data vault.

Andy Murphy

Written by

Andy Murphy

Director of content, industrials

Real estate

Results update

28 October 2025

Price 54.90p
Market cap £163m

Net cash/(debt) at 30 June 2025

£(18.2)m

Shares in issue

296.8m
Free float 100.0%
Code FOXT
Primary exchange LSE
Secondary exchange N/A
Price Performance
% 1m 3m 12m
Abs (1.4) (12.3) (5.7)
52-week high/low 68.9p 49.4p

Business description

Foxtons Group is London’s leading and most widely recognised estate agency. It operates from a network of interconnected branches offering a range of residential-related services, which are split into three separate revenue streams: sales, lettings and mortgage broking.

Next events

FY25 trading update

End-January 2025

FY25 results

March 2026

Analyst

Andy Murphy
+44 (0)20 3077 5700

Foxtons Group is a research client of Edison Investment Research Limited

Note: PBT and EPS include amortisation of acquired intangibles and exceptional items (ie diluted company definition).

Year end Revenue (£m) PBT (£m) EPS (p) DPS (p) P/E (x) Yield (%)
12/23 147.1 7.9 3.21 0.90 17.1 1.6
12/24 163.9 17.5 4.93 1.17 11.1 2.1
12/25e 173.9 17.4 4.95 1.30 11.1 2.4
12/26e 180.8 21.6 6.12 1.50 9.0 2.7

Q325 revenue growth slowed to 3%

Foxtons’ group revenue amounted to £49.0m in Q3, implying growth of 3%. Lettings, the largest division, grew revenue by 5%, and Financial Services revenue rose 37%. However, Sales, previously the fastest-growth division, was affected by reduced consumer confidence ahead of the Autumn Budget and its revenue reduced 7%. Furthermore, the change in stamp duty in Q1 pulled volumes forward to that period, affecting Q2 and Q3 volumes.

Positive trends and actions

There are a number of trends and initiatives that are expected to positively affect Foxtons’ markets and/or profits. These include the Renters’ Rights Bill, which is approaching its final stages in Parliament. This is likely to help drive private landlords towards professional property management services. Foxtons has also launched a new people initiative called ‘Getting It Done. Together’ (GIDT), which aims to foster a more respectful, rewarding and inspiring culture within the group. Finally, the company announced another £3m share buyback in September and is well advanced with plans to relocate its head office, which will deliver meaningful cost savings from January 2026.

Valuation: Estimate revisions and adjustments

Given the clear market weakness in Sales in Q325 and the uncertainty that already-agreed sales will compete on the timescale expected in Q4, Foxtons has guided down market expectations of adjusted operating profit from a consensus of £23.7m, to £21.5–23.2m. We have reduced our FY25, FY26 and FY27 expectations accordingly and have adjusted our valuation from 134p per share to 126p per share.

Sales volumes in Q425 subject to volatility

There is little doubt that the reorganisation and reinvigoration of Foxtons, as well as the revised strategic targets, are driving positive change. However, in Q3, the confidence that had been in the sales market has evaporated as the media has picked up on discussions surrounding the now-delayed Autumn Budget and the potential for further tax rises. This suggests that Q4 is likely to be less promising than previously assumed. Therefore, we have reduced our FY25, FY26 and FY27 estimates as it is unclear what level of agreed sales will complete by year-end considering the market uncertainty. Despite this, Foxtons continues to drive the business and improve its internal functions even if the outside markets are less forgiving.

Year-to-date revenue and Q3 results driven by non-cyclical business

Foxtons’ Q325 results demonstrated overall revenue growth of 3% to £49.0m, but this hides the weaker market-led performance in Sales, where reduced consumer confidence led to lower levels of sales activity in the period. There was also evidence that the stamp duty change at the end of Q1 also contributed to the quarter’s weakness. In the nine-month year-to-date period (9M25), overall revenue increased 7% to £135.1m, with that growth spread more equitably over the three divisions. Looking at the table below, 9M25 group revenue is up more than 60% on the 9M19 pre-COVID-19 comparative period.

Q3 Lettings revenue increased by 5% (or £1.8m) to £33.4m, driven by £0.6m of like-for-like growth (operational improvements, enhanced portfolio retention, new deals and rental price lifts) and £1.5m from acquisitions, offset by a £0.3m reduction in the interest earned on client money. 9M25 Lettings revenue, accounting for 65% of year-to-date revenue, increased 5% to £88.0m, which included £4.4m from incremental acquisitions, offset by a £0.8m reduction in interest on client money.

In Sales, Q3 revenue declined 7.4% to £12.5m as exchange volumes decreased due to lower volumes of market transactions. Buyer activity was affected by deals pulled into Q125 due to the stamp duty deadline, more limited interest rate reductions than had been expected and uncertainty surrounding the delayed Autumn Budget. Year-to-date revenue increased 12.3% to £39.4m, benefitting from the strong Q1 period, boosted by the stamp duty deadline.

The smallest division, Financial Services, saw Q3 revenue increase 37% to £3.1m, benefitting from the expected bounce in remortgage activity (relating to original deals taken out in the early period of COVID-19) and new purchase mortgage activity, which was stable, despite the weaker sales market, underscoring the resilience of the re-finance portfolio. Good operational progress relating to lead generation and adviser productivity growth strategies contributed to strength. Year-to-date revenue was up 12% to £7.7m.

Continued strategic development

Exhibit 2 below highlights the divisional revenue trends. Clearly, Lettings has grown steadily in each of the last five years in contrast to Sales and Financial Services, as the underlying markets have been quite volatile, driven by outside influences. Revenue in both Sales and Financial Services has grown in 9M25, compared to 9M24 and, despite the evident volatility, the revenues of both divisions are comfortably higher than they were in 9M19. This, in our opinion, reflects the active investment in fee earners, staff training, data suites and the Foxtons brand, especially recently.

Exhibit 3 below shows the growth rates of the three divisions in Q325 versus the same period in 2019 and in 9M25 versus 9M19. This suggests that the business has been performing well, benefitting from the management initiatives mentioned above.

Modest profit downgrade as market caution affects sales

Given the uncertainty that prevails currently, Foxtons has guided down its FY25 adjusted operating profit estimates from a consensus figure of £23.7m, to £21.5–23.2m, depending on the level of completions of agreed sales under-offer pipeline in Q4. Lettings is expected to continue to trade broadly in line with the first nine-months and Financial Services is expected to perform well, although it is the smallest division.

Our revised FY25 adjusted operating profit estimate moves from £23.6m to £22.0m, with a corresponding downgrade for FY26 as well. Net debt moves out modestly as well. Despite this, Foxtons remains well-placed to benefit in the medium term, after the Autumn Budget removes uncertainty, and there also remains the potential for interest rates decrease. Furthermore, Foxtons expects to benefit longer term from its rebuilt operational capabilities.

General disclaimer and copyright

This report has been commissioned by Foxtons Group and prepared and issued by Edison, in consideration of a fee payable by Foxtons Group. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2025 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or sol icitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

More on Foxtons Group

View All

Latest from the Real Estate sector

View All Real Estate content

Research: Investment Companies

BB Biotech — Turning milestones into momentum

BB Biotech (BION) delivered strong Q325 results, underpinned by its focus on innovative biotech companies with differentiated clinical pipelines and promising long-term potential. NAV increased 24.0% (in CHF terms) and its share price rose 20.0%, both comfortably outperforming BION’s benchmark, the Nasdaq Biotech Index (15.7%). The most recent quarter benefited from improving macroeconomic conditions, including the Federal Reserve’s first rate cut in September. The sector outlook remains favourable, with M&A expected to be a key performance driver as big pharmaceutical companies replenish their pipelines ahead of a looming patent cliff. Several core portfolio holdings achieved significant clinical and regulatory milestones, supporting BION’s momentum, and others are anticipated before year-end, serving as potential near-term catalysts for portfolio performance.

Continue Reading